PDF(514 KB)
血管内皮生长因子及其受体抑制剂相关性高血压病理生理机制及临床诊疗的研究进展
张莉,夏彬凤,黄慧慧,王茹,孔敏,尹霞
PDF(514 KB)
PDF(514 KB)
血管内皮生长因子及其受体抑制剂相关性高血压病理生理机制及临床诊疗的研究进展
)Research progress in pathophysiological mechanism and clinical diagnosis and treatment of hypertension associated with vascular endothelial growth factor and its receptor inhibitors
)肿瘤治疗相关心血管毒性（CTR-CVT）逐渐成为影响肿瘤幸存者预后的关键因素。以血管内皮生长因子（VEGF）为靶点研发的VEGF及其受体抑制剂（VEGFIs）作为新型抗肿瘤药物现已广泛应用于临床，可延长肿瘤患者的生存周期，改善患者预后，但VEGFIs诱导的高血压作为其最常见的CTR-CVT，可能会限制和影响其应用并引起严重心血管疾病（CVD）。对应用VEGFIs治疗的肿瘤患者应密切监测血压，早期评估，优化管理，使患者获得最佳的抗肿瘤疗效和最低的CTR-CVT风险。现就VEGFIs相关性高血压的临床表现、发病机制、诊断和治疗策略进行综述，旨在为临床医生更好地管理和应对VEGFIs相关性高血压提供参考。
Cancer therapy-related cardiovascular toxicity（CTR-CVT） is gradually becoming a critical factor affecting the prognosis of cancer survivors. Vascular endothelial growth factor （VEGF） and its receptor inhibitors （VEGFIs）， developed as novel anti-cancer drugs targeting VEGF， are now widely used in clinical practice. They can extend the survival period of the cancer patients and improve the prognosis of the patients. However， the hypertension induced by VEGFIs， as the most common CTR-CVT， may limit and impact their use and leads to severe cardiovascular diseases （CVD）. It is essential to closely monitor blood pressure in the cancer patients treated with VEGFIs， conduct early assessments， and optimize the management to achieve the best anti-cancer efficacy and minimize the risk of CTR-CVT. This review discusses the clinical manifestations， pathogenesis， diagnosis， and treatment strategies of VEGFIs-related hypertension， in order to provide better guidances for managing and addressing VEGFIs-related hypertension for the clinicians.
抗肿瘤药物 / 血管内皮生长因子及其受体抑制剂 / 血管内皮生长因子受体抑制剂 / 肿瘤治疗相关心血管毒性 / 高血压
Antineoplastic drug / Vascular endothelial growth factors and its receptor inhibitor / Vascular endothelial growth factor receptor inhibitor / Cancer therapy-related cardiovascular toxicity / Hypertension
R544.1
| 1 | LYON A R， LóPEZ-FERNáNDEZ T， COUCH L S， et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association （EHA）， the European Society for Therapeutic Radiology and Oncology （ESTRO） and the International Cardio-Oncology Society （IC-OS）［J］. Eur Heart J， 2022， 43（41）： 4229-4361. |
| 2 | TOTZECK M， SCHULER M， STUSCHKE M， et al. Cardio-oncology-strategies for management of cancer-therapy related cardiovascular disease［J］. Int J Cardiol， 2019， 280： 163-175. |
| 3 | WILLIAMS B， MANCIA G， SPIERING W， et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension［J］. Eur Heart J， 2018， 39（33）： 3021-3104. |
| 4 | QUINTANILHA J C F， WANG J， SIBLEY A B， et al. Bevacizumab-induced hypertension and proteinuria： a genome-wide study of more than 1000 patients［J］. Br J Cancer， 2022， 126（2）： 265-274. |
| 5 | LI M G， MULKEY F， JIANG C， et al. Identification of a genomic region between SLC29A1 and HSP90AB1 associated with risk of bevacizumab-induced hypertension： CALGB 80405 （alliance）［J］. Clin Cancer Res， 2018， 24（19）： 4734-4744. |
| 6 | 杨晓蕾， 管 博， 吕海辰， 等. 抗癌药物血管内皮生长因子抑制剂相关高血压的管理策略［J］. 中华心血管病杂志， 2021， 49（10）： 957-962. |
| 7 | CALETTI S， PAINI A， COSCHIGNANO M A， et al. Management of VEGF-targeted therapy-induced hypertension［J］. Curr Hypertens Rep， 2018， 20（8）： 68. |
| 8 | VERSMISSEN J， MIRABITO COLAFELLA K M， KOOLEN S L W， et al. Vascular Cardio-Oncology： Vascular Endothelial Growth Factor inhibitors and hypertension［J］. Cardiovasc Res， 2019， 115（5）： 904-914. |
| 9 | CIGNARELLA A， FADINI G P， BOLEGO C， et al. Clinical efficacy and safety of angiogenesis inhibitors： sex differences and current challenges［J］. Cardiovasc Res， 2022， 118（4）： 988-1003. |
| 10 | RAMJIAWAN R R， GRIFFIOEN A W， DUDA D G. Anti-angiogenesis for cancer revisited： is there a role for combinations with immunotherapy？［J］. Angiogenesis， 2017， 20（2）： 185-204. |
| 11 | IVANYI P， BEUTEL G， DREWES N， et al. Therapy of treatment-related hypertension in metastatic renal-cell cancer patients receiving sunitinib［J］. Clin Genitourin Cancer， 2017， 15（2）： 280-290.e3. |
| 12 | ROVIELLO G， PACIFICO C， CORONA P， et al. Risk of hypertension with ramucirumab-based therapy in solid tumors： data from a literature based meta-analysis［J］. Invest New Drugs， 2017， 35（4）： 518-523. |
| 13 | QI W X， SHEN Z， TANG L N， et al. Risk of hypertension in cancer patients treated with aflibercept： a systematic review and meta-analysis［J］. Clin Drug Investig， 2014， 34（4）： 231-240. |
| 14 | QI W X， HE A N， SHEN Z， et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients： a systematic review and meta-analysis［J］. Br J Clin Pharmacol， 2013， 76（3）： 348-357. |
| 15 | B?K M?LLER N， BUDOLFSEN C， GRIMM D， et al. Drug-induced hypertension caused by multikinase inhibitors （sorafenib， sunitinib， lenvatinib and axitinib） in renal cell carcinoma treatment［J］. Int J Mol Sci， 2019， 20（19）： 4712. |
| 16 | WU H X， DING X Y， ZHANG Y C， et al. Incidence and risk of hypertension with lenvatinib in treatment of solid tumors： an updated systematic review and meta-analysis［J］. J Clin Hypertens， 2022， 24（6）： 667-676. |
| 17 | CHEN J X， WANG J H. Risk of regorafenib-induced cardiovascular events in patients with solid tumors： a systematic review and meta-analysis［J］. Medicine， 2018， 97（41）： e12705. |
| 18 | WANG Z X， XU J， NIE W W， et al. Risk of hypertension with regorafenib in cancer patients： a systematic review and meta-analysis［J］. Eur J Clin Pharmacol， 2014， 70（2）： 225-231. |
| 19 | MILLING R V， GRIMM D， KRüGER M， et al. Pazopanib， cabozantinib， and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension［J］. Int J Mol Sci， 2018， 19（10）： 3258. |
| 20 | PINKHAS D， HO T， SMITH S. Assessment of pazopanib-related hypertension， cardiac dysfunction and identification of clinical risk factors for their development［J］. Cardiooncology， 2017， 3： 5. |
| 21 | YANG X W， PAN X， CHENG X S， et al. Risk of hypertension with sorafenib use in patients with cancer： a meta-analysis from 20， 494 patients［J］. Am J Ther， 2017， 24（1）： e81-e101. |
| 22 | MOTZER R， ALEKSEEV B， RHA S Y， et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma［J］. N Engl J Med， 2021， 384（14）： 1289-1300. |
| 23 | QI W X， SHEN Z， LIN F， et al. Incidence and risk of hypertension with vandetanib in cancer patients： a systematic review and meta-analysis of clinical trials［J］. Br J Clin Pharmacol， 2013， 75（4）： 919-930. |
| 24 | CHOUEIRI T K， HESSEL C， HALABI S， et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk （Alliance A031203 CABOSUN randomised trial）： progression-free survival by independent review and overall survival update［J］. Eur J Cancer， 2018， 94： 115-125. |
| 25 | HONG S， DANIELS B， VAN LEEUWEN M T， et al. Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors［J］. Discov Oncol， 2022， 13（1）： 6. |
| 26 | VAN DORST D C H， KABADAYI S， OOMEN-DE HOOP E， et al. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise： a clinical cohort study［J］. J Am Heart Assoc， 2023， 12（1）： e028050. |
| 27 | COLLINS T， GRAY K， BISTA M， et al. Quantifying the relationship between inhibition of VEGF receptor 2， drug-induced blood pressure elevation and hypertension［J］. Br J Pharmacol， 2018， 175（4）： 618-630. |
| 28 | QUINTANILHA J C F， LIU Y M， ETHERIDGE A S， et al. Plasma levels of angiopoietin-2， VEGF-A， and VCAM-1 as markers of bevacizumab-induced hypertension： CALGB 80303 and 90401 （Alliance）［J］. Angiogenesis， 2022， 25（1）： 47-55. |
| 29 | CORTI F， SIMONS M. Modulation of VEGF receptor 2 signaling by protein phosphatases［J］. Pharmacol Res， 2017， 115： 107-123. |
| 30 | 赵小建， 王 琛， 刘 敏， 等. 抗血管生成靶向药物导致高血压的研究进展［J］. 临床荟萃， 2020， 35（8）： 749-754. |
| 31 | MUKAI M， KOMORI K， OKA T. Mechanism and management of cancer chemotherapy-induced atherosclerosis［J］. J Atheroscler Thromb， 2018， 25（10）： 994-1002. |
| 32 | LANKHORST S， BAELDE H J， KAPPERS M H， et al. Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib［J］. Hypertension， 2015， 66（3）： 543-549. |
| 33 | M?KI-PET?J? K M， MCGEOCH A， YANG L L， et al. Mechanisms underlying vascular endothelial growth factor receptor inhibition-induced hypertension： the HYPAZ trial［J］. Hypertension， 2021， 77（5）： 1591-1599. |
| 34 | NEVES K B， RIOS F J， VAN DER MEY L， et al. VEGFR （vascular endothelial growth factor receptor） inhibition induces cardiovascular damage via redox-sensitive processes［J］. Hypertension， 2018， 71（4）： 638-647. |
| 35 | VAN DEN MEIRACKER A H， DANSER A H. Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition［J］. Hypertension， 2016， 68（1）： 17-23. |
| 36 | 蒋 慧， 丁国华. VEGF 对肾脏调节作用的研究进展［J］. 医学研究杂志， 2017， 46（11）： 182-185. |
| 37 | IZZEDINE H， ESCUDIER B， LHOMME C， et al. Kidney diseases associated with anti-vascular endothelial growth factor （VEGF）： an 8-year observational study at a single center［J］. Medicine， 2014， 93（24）： 333-339. |
| 38 | ESTRADA C C， MALDONADO A， MALLIPATTU S K. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities［J］. J Am Soc Nephrol， 2019， 30（2）： 187-200. |
| 39 | BELCIK J T， QI Y， KAUFMANN B A， et al. Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer［J］. J Am Coll Cardiol， 2012， 60（7）： 618-625. |
| 40 | THIJS A， VAN HERPEN C， VAN DER GRAAF W T A， et al. Early rise in aldosteron is correlated with increase in blood pressure in sunitinib treated patients with metastatic renal cell carcinoma［J］. Clin Ther， 2014， 36（8）： e11. |
| 41 | GENNARI-MOSER C， KHANKIN E V， ESCHER G， et al. Vascular endothelial growth factor-A and aldosterone： relevance to normal pregnancy and preeclampsia［J］. Hypertension， 2013， 61（5）： 1111-1117. |
| 42 | KAPPERS M H， VAN ESCH J H， SLUITER W， et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels［J］. Hypertension， 2010， 56（4）： 675-681. |
| 43 | PANDEY A K， SINGHI E K， ARROYO J P， et al. Mechanisms of VEGF （vascular endothelial growth factor） inhibitor-associated hypertension and vascular disease［J］. Hypertension， 2018， 71（2）： e1-e8. |
| 44 | LANKHORST S， SEVERS D， MARKó L， et al. Salt sensitivity of angiogenesis inhibition-induced blood pressure rise： role of interstitial sodium accumulation？［J］. Hypertension， 2017， 69（5）： 919-926. |
| 45 | TOUYZ R M， LANG N N， HERRMANN J， et al. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition［J］. Hypertension， 2017， 70（2）： 220-226. |
| 46 | LOMBARDI P， ROSSINI D， CRESPI V， et al. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer： an individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature［J］. Cancer Treat Rev， 2022， 103： 102326. |
| 47 | OSUMI H， SHINOZAKI E， OOKI A， et al. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy［J］. Cancer Med， 2021， 10（2）： 615-625. |
| 48 | DUCO M R， MURDOCK J L， REEVES D J. Vascular endothelial growth factor inhibitor induced hypertension： retrospective analysis of the impact of blood pressure elevations on outcomes［J］. J Oncol Pharm Pract， 2022， 28（2）： 265-273. |
| 49 | DUFFAUD F， SLEIJFER S， LITIèRE S， et al. Hypertension （HTN） as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer （EORTC） 62043 and 62072 trials［J］. Eur J Cancer， 2015， 51（17）： 2615-2623. |
| 50 | HURWITZ H I， DOUGLAS P S， MIDDLETON J P， et al. Analysis of early hypertension and clinical outcome with bevacizumab： results from seven phase Ⅲ studies［J］. Oncologist， 2013， 18（3）： 273-280. |
| 51 | 熊宇麒， 李学军. 心血管疾病与恶性肿瘤的共同危险因素及药物的影响［J］. 药学学报， 2020， 55（1）： 1-7. |
| 52 | MEHTA L S， WATSON K E， BARAC A， et al. Cardiovascular disease and breast cancer： where these entities intersect： a scientific statement from the American heart association［J］. Circulation， 2018， 137（8）： e30-e66. |
| 53 | CURIGLIANO G， LENIHAN D， FRADLEY M， et al. Management of cardiac disease in cancer patients throughout oncological treatment： ESMO consensus recommendations［J］. Ann Oncol， 2020， 31（2）： 171-190. |
| 54 | MCDONAGH T A， METRA M， ADAMO M， et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure［J］. Eur Heart J， 2021， 42（36）： 3599-3726. |
| 55 | VAN DORST D C H， DOBBIN S J H， NEVES K B， et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients［J］. Circ Res， 2021， 128（7）： 1040-1061. |
| 56 | PINTER M， KWANTEN W J， JAIN R K. Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events［J］. Clin Cancer Res， 2018， 24（16）： 3803-3812. |
| 57 | WALIANY S， SAINANI K L， PARK L S， et al. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor［J］. JACC CardioOncol， 2019， 1（1）： 24-36. |
| 58 | ZAMORANO J L， LANCELLOTTI P， RODRIGUEZ MU?OZ D， et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines： ?The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology （ESC）［J］. Eur Heart J， 2016， 37（36）： 2768-2801. |
| 59 | DE MACEDO ANDRADE A C， FELIX F A， FRAN?A G M， et al. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma： a systematic review and meta-analysis［J］. Eur J Clin Pharmacol， 2022， 78（6）： 919-930. |
| 60 | COHEN J B， BROWN N J， BROWN S A， et al. Cancer therapy-related hypertension： a scientific statement from the American heart association［J］. Hypertension， 2023， 80（3）： e46-e57. |
/
| 〈 |
|
〉 |
AI Summary
